Please assess the completion status of the following clinical trial:

Trial Title: Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathology confirmation of HL with City of Hope (COH) pathology review~* Hodgkin lymphoma that is:~  * PIF (primary induction failure): did not enter complete remission with first line of therapy; Note: a patient with PIF who responds to salvage therapy with a PR or CR is also eligible (and would be considered PIF-sensitive)~ * Early 1st relapse: initial CR of \> 3 months and \< 12 months after 1st line chemotherapy~ * 1st relapsed HL in a patient who is not in CR after 2 cycles of salvage therapy~ * In 2nd or subsequent relapse (RL) whether in CR or not after salvage therapy~* Relapse/persistent disease evidenced by a computed tomography and fluorodeoxyglucose (FDG)-positron emission tomography (PET), or bone marrow biopsy~* Cardiac ejection fraction of \>= 50% by echocardiogram or multi gated acquisition scan (MUGA)~* Forced expiratory volume in one second (FEV1) \> 65% of predicted measured, or diffusion capacity of the lung for carbon monoxide (DLCO) \>= 50% of predicted measured~* Bilirubin =\< 1.5 x normal~* Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =\< 2 x normal except in cases where abnormal liver function tests (LFTS) are due to involvement with HL~* Serum creatinine of =\< 1.5 mg/dL, and a measured creatinine clearance of \>= 60 mL/min~* Karnofsky status \>= 70%~* Life expectancy \>= 6 months~* Females must not be pregnant or breast feeding, and must use accepted birth control methods; males must use accepted birth control methods~* Capability of providing informed consent~* Patients will be enrolled after receiving at least two cycles of salvage cytoreductive chemotherapy and collection of at least 3.0 x 10\^6 CD34 cells/kg of autologous hematopoietic progenitor cells (HPC-A) by apheresis; a minimum of 2 collection procedures is required, unless collection on day #1 \> 5.0 x 10\^6 CD34 cells/kg; a maximum of 10 collections is allowed; bone marrow harvest to supplement apheresis is not allowed~* Co-enrollment on Institutional Review Board (IRB) #98117, entitled Molecular Pathogenesis of Therapy-Related Leukemia~* All pre-study and follow-up imaging studies preferably performed at City of Hope~* Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to =\< grade 2 (Common Terminology Criteria for Adverse Events version 4 \[CTCAE v4\])~* Body mass index (BMI) \> 30% will be considered on a case-by-case basis by the radiation oncology principal investigator (PI)~* While on this study, patients may not be treated with any other investigational agent for any purpose until relapse or progression~Exclusion Criteria:~* Lymphocyte-predominant Hodgkin lymphoma~* Prior high dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation~* Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records by the radiation oncology PI; patients who have had prior external beam radiation \> 2000 cGy (at 180 to 200 cGy per day) to any portion of the lung will be ineligible; patients with ANY prior radiation to the heart are ineligible; patients with \> 500 cGy to any portion of the kidney will be excluded from the study~* Presence of antibody against basiliximab (only required for patients who have received prior antibody)~* Myelodysplasia or any active malignancy other than HL, or \< 5 years remission from any other prior malignancy, except adequately treated basal cell or squamous cell carcinoma~* Active hepatitis B or C viral infection or hepatitis B surface antigen positive~* Positive human immunodeficiency virus antibody~* Patients with psychosocial circumstances or illnesses that preclude protocol participation (to be determined by PI)~* Co-morbid illnesses that preclude protocol participation (to be determined by PI)~* Any cytogenetic abnormality in the bone marrow that is known to be associated with or predictive of myelodysplasia is excluded. This includes, but is not limited to, del(5), del(7), del(11)~* Persistent marrow involvement (\> 10%) with HL after salvage cytoreductive therapy and before stem cell mobilization~* Systemic chemotherapy or radiation within 4 weeks prior to the Y-90 dose of radioimmunotherapy (RIT), with the exception of single agent Cytoxan priming chemotherapy administered for mobilization~* Bone marrow (BM) harvest required to reach adequate cell dose for transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (radiolabeled monoclonal antibody, chemotherapy) (Type: EXPERIMENTAL): DOSIMETRY STUDY: Patients receive basiliximab IV and indium In 111 basiliximab IV on day -21. Patients undergo indium In 111 imaging scans daily. Patients with appropriate biodistribution continue on to treatment.~TREATMENT: Patients receive basiliximab IV and yttrium Y 90 basiliximab IV on day -14. Patients also receive BEAM chemotherapy comprising carmustine IV over 2 hours on days -7 and -6, etoposide IV BID over 4 hours and cytarabine IV over 2 hours BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic progenitor cell infusion on day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).